Literature DB >> 12726730

Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.

Amber D Steele1, Earl E Henderson, Thomas J Rogers.   

Abstract

A substantial proportion of HIV-1-infected individuals are intravenous drug users (i.v.DUs) who abuse opiates. Opioids induce a number of immunomodulatory effects that may directly influence HIV-1 disease progression. In the present report, we have investigated the effect of opioids on the expression of the major HIV-1 coreceptors CXCR4 and CCR5. For these studies we have focused on opiates which are ligands for the mu-opioid receptor. Our results show that DAMGO, a selective mu-opioid agonist, increases CXCR4 and CCR5 expression in both CD3(+) lymphoblasts and CD14(+) monocytes three- to fivefold. Furthermore, DAMGO-induced elevation of HIV-1 coreceptor expression translates into enhanced replication of both X4 and R5 viral strains of HIV-1. We have confirmed the role of the mu-opioid receptor based on the ability of a mu-opioid receptor-selective antagonist to block the effects of DAMGO. We have also found that morphine enhances CXCR4 and CCR5 expression and subsequently increases both X4 and R5 HIV-1 infection. We suggest that the capacity of mu-opioids to increase HIV-1 coreceptor expression and replication may promote viral binding, trafficking of HIV-1-infected cells, and enhanced disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12726730     DOI: 10.1016/s0042-6822(03)00015-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  85 in total

1.  OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV.

Authors:  Nicole R Nugent; Michelle A Lally; Larry Brown; Valerie S Knopik; John E McGeary
Journal:  AIDS Behav       Date:  2012-11

2.  CXCR4 signaling mediates morphine-induced tactile hyperalgesia.

Authors:  Natalie M Wilson; Hosung Jung; Matthew S Ripsch; Richard J Miller; Fletcher A White
Journal:  Brain Behav Immun       Date:  2010-12-28       Impact factor: 7.217

Review 3.  Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms.

Authors:  Shilpa Buch; Honghong Yao; Minglei Guo; Tomohisa Mori; Blaise Mathias-Costa; Vijeta Singh; Pankaj Seth; John Wang; Tsung-Ping Su
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 4.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

5.  Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages.

Authors:  Rajnish S Dave
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03

Review 6.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

7.  Critical Role of Beclin1 in HIV Tat and Morphine-Induced Inflammation and Calcium Release in Glial Cells from Autophagy Deficient Mouse.

Authors:  Jessica Lapierre; Myosotys Rodriguez; Chet Raj Ojha; Nazira El-Hage
Journal:  J Neuroimmune Pharmacol       Date:  2018-05-11       Impact factor: 4.147

8.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

9.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

10.  Opiate-induced hypernociception and chemokine receptors.

Authors:  Fletcher White; Natalie Wilson
Journal:  Neuropharmacology       Date:  2009-07-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.